the aid library

LIST OPTIONS

Filter

4406

Sort by:

Direction:

Download (150)

View PDF (219)

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection - AIDSinfo

AIDSinfo (2019) C2

Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019 Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office of AIDS Research Advisory Council (OARAC)

Download (149)

View PDF (188)

Developmental roadmap for antimicrobial susceptibility testing systems

Belkum, A.van, T. T. Bachmann, G. Lüdke, et al. (2019) CC

Nature Reviews Microbiology Vol. 17 (2019)pp.51-62 Antimicrobial susceptibility testing (AST) technologies help to accelerate the initiation of targeted antimicrobial therapy for patients with infections and could potentially extend the lifespan of current narrow- spectrum antimicrobials. Althoug... more

Download (354)

View PDF (529)

Guidelines for the Management of Multidrug-Resistant Tuberculosis (MDR-TB) in Myanmar

The Republic of the Union of Myanmar, Ministry of Health, Department of Health, National Tuberculosis Programme (2013) C_WHO

Following the encouraging initial results of the pilot project, the Ministry of Health is committed to increasing access to MDR-TB diagnosis, treatment and care. An expansion plan for the programmatic management of drug-resistant TB has been developed and forms part of the Five Year National Strateg... more

Download (784)

View PDF (692)

National Guidelines on Second-line ART for Adults and Adolescents India

National AIDSControl (NACO), Government of India; Ministry of Health and Family Welfare (2011) C1

This resource consists of technical guidelines for District Medical Officers, counselors and laboratory technicians for second-line antiretroviral therapy drugs, operational guidelines for pilot roll-out in two centres and laboratory guidelines for viral-load testing and standard operating procedure... more

Download (7468)

View PDF (1871)

The fight against fake drugs by NAFDAC in Nigeria

The fight against fake drugs by NAFDAC in Nigeria Olike Chinwendu KIT (Royal Tropical Institute) Development Policy & Practice Vrije Universiteit Amsterdam (2008) CC

Review over the work and challenges of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) in combatting counterfeiting of medicines in Nigeria.

Download (31)

View PDF (32)

Primary and Secondary Prevention of Ischemic Stroke

Paciaroni, M.; Bogousslavsky, J. European Neurology (2010) CC

Prevention of stroke and transient ischemic attack includes both conventional approaches to vascular risk factor management (blood pressure lowering, cholesterol reduction with statins, smoking cessation and antiplatelet therapy) and more specific interventions, such as carotid revascularization or... more

Download (96)

View PDF (365)

Chagas Clinical Research Platform

Drugs for Neglected Diseases Initiative DNDi Latin America (2022) CC

To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f... more

Download (136)

View PDF (159)

National Action Plan of the Islamic Republic of Iran for combating antimicrobial resistance

Ministry of Health and Medical Education Iran (2016) C_WHO

Antimicrobial resistance is one of the most important threats to the health worldwide. Antimicrobial resistance or drug resistance is the reduction of the pharmaceutical effects of a drug against a disease or reduction of its effectiveness in improving the clinical signs of a disease. Antimicrobial ... more

Download (1508)

View PDF (1912)

PIH Guide to the Medical Management of MDR-TB

USAID; TB Care; DRTB Training Network (2014) C1

This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.

Download (157)

View PDF (196)

Management of epilepsy in women of child bearing age

World Health Organization (2012) C_WHO

Q11: 11a). In women with epilepsy, should antiepileptic therapy be prescribed as monotherapy or polytherapy to decrease the risk of fetal malformations? 11b). Does the use of folic acid preconceptually decrease the risk of foetal malformations in women with epilepsy? 11c). Do phenytoin, phenobarbi... more

Download (639)

View PDF (3099)

Guidelines - European AIDS Clinical Society (EACS)

European AIDS Clinical Society (EACS) European AIDS Clinical Society (EACS) (2020) C2

Version 10.1_5 October 2020 These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website. The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview ... more

Download (32)

View PDF (44)

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Guo, J.; Garratt, A.; Hill, A. Journal of Cystic Fibrosis (2022) CC

Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma... more

Download (263)

View PDF (358)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (111)

View PDF (129)

The role of HIV viral suppression in improving individual health and reducing transmission

World Health Organisation (WHO) (2023) C_WHO

This policy brief describes key HIV viral load thresholds and the available viral load testing approaches for monitoring how well antiretroviral therapy is working for people living with HIV. It provides clarification for and elaborates upon the current treatment monitoring algorithm from the Consol... more

Download (136)

View PDF (188)

WHO interim guidelines for the treatment of gambiense human African trypanosomiasis

World Health Organization WHO (2019) C_WHO

This document focuses on the management of patients affected by gambiense HAT and constitutes an update to the WHO therapeutic guidance issued in 2013. The main changes in recommendations concern the criteria and methods for deciding the treatment among the new set of therapeutic options and the pa... more

Download (90)

View PDF (1366)

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
recommended

Turkova, A.; G.H. Wills, E. Wobudeya, et al. (2022) C2

N Engl J Med 2022; 386:911-922, DOI: 10.1056/NEJMoa2104535 Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis (SHINE Study)

Download (129)

View PDF (166)

High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries

Bortone, B.; et al. (2021) CC

PlosOne January 20, 2021 https://doi.org/10.1371/journal.pone.0241899 Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving effectiveness and adherence to therapy. However, high use of potentially inappropriate FDCs has been reported, with implications for antim... more

Download (166)

View PDF (180)

The Importance of Pharmacovigilance

World Health Organization WHO (2020) C_WHO

The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug... more

Download (184)

View PDF (234)

HIV and tuberculosis co-infection programmes

Avert Avert (2019) C2

People living with HIV who have a low CD4 count are at a much higher risk of falling ill from TB infection than HIV negative people. It is important to offer both HIV testing to TB patients and TB diagnosis in HIV patients. Early detection and effective treatment are essential to preventing TB... more

Download (112)

View PDF (128)

Management & Post-Exposure Prophylaxis of Potential HIV and Hepatitis B Exposure in Children, Adolescents & Adults Guidelines (South Africa)

Western Cape Government Health, South Africa (2019) C1

1PEP GUIDELINES | 2019 EDITION. The prevalence of both HIV and Hepatitis B is high in South Africa therefore there is a significant risk of acquiring these infections following exposure to infected material. Studies suggest that post- exposure prophylaxis (PEP) with highly active antiretroviral trea... more

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children recommended

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
recommended